Variation in results from randomized, controlled trials: stochastic or systematic?

被引:22
|
作者
Jane-wit, Daniel [2 ]
Horwitz, Ralph I. [2 ]
Concato, John [1 ,3 ]
机构
[1] VA CT Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT 06516 USA
[2] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
[3] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA
关键词
Randomized controlled trials; Validity (epidemiology); Evidence-based medicine; Clinical epidemiology; External validity (generalizability); Accuracy; CLINICAL-TRIALS; HEART-FAILURE; BLOOD-PRESSURE; METAANALYSIS; DISEASE; INHIBITORS; CELECOXIB; BLOCKERS; RISK; BIAS;
D O I
10.1016/j.jclinepi.2009.02.010
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Randomized controlled trials (RCTs) are considered the highest grade of research evidence, yet properly conducted trials investigating the same association often yield conflicting, results. Our objective was to assess whether variability in treatment protocols of RCTs investigating the same topic could explain distinct patterns of outcomes. Study Design and Setting: A review of meta-analyses identified clinical topics involving RCTs with variable pharmacologic dosing and disparate outcomes. Topics were retained if at least two pairs of trials had results suggesting contradictory yet strong exposure-outcome associations. Results: The search yielded 6 clinical topics and 58 RCTs, and individual RCTs were classified into two groups, based on low and high dosages of the intervention. Aggregate odds ratios for studies in the low- and high-dose groups were often substantially discordant. For example, odds ratios were 1.76 (95% confidence interval [CI] = 1.02-3.03) for low-dose and 0.56 (95% CI = 0.31-1.03) for high-dose trials evaluating low-molecular weight heparin and pulmonary embolism. In an exploratory analysis, Outcomes for low- and high-dose groups in the comparison arms of trials (including patients assigned to placebo) had statistically significant differences in four of five analyzable topics, suggesting differences in patient characteristics across trials. Conclusion: Conflicting results from RCTs can represent a spectrum of "real" outcomes for specific treatments. Such trials are best evaluated by considering concurrently both the validity of study design as well as the generalizability of patients and interventions involved. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:56 / 63
页数:8
相关论文
共 50 条
  • [1] Effect of nut consumption on vascular endothelial function: A systematic review and meta-analysis of randomized controlled trials
    Xiao, Yunjun
    Huang, Wei
    Peng, Chaoqiong
    Zhang, Jinzhou
    Wong, Carmen
    Kim, Jean H.
    Yeoh, Eng-kiong
    Su, Xuefen
    CLINICAL NUTRITION, 2018, 37 (03) : 831 - 839
  • [2] Many scenarios exist for selective inclusion and reporting of results in randomized trials and systematic reviews
    Page, Matthew J.
    McKenzie, Joanne E.
    Forbes, Andrew
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2013, 66 (05) : 524 - 537
  • [3] Systematic review on the quality of randomized controlled trials from Saudi Arabia
    Rajab, Ahmad Mamoun
    Hamza, Abdulmalik
    Aldairi, Roshdi Kotaiba
    Alaloush, Mohamad Mahmoud
    Saquib, Juliann
    Saquib, Nazmus
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 16
  • [4] The effectiveness of Baduanjin exercise for hypertension: a systematic review and meta-analysis of randomized controlled trials
    Shao, Bao-yi
    Zhang, Xia-tian
    Vernooij, Robin W. M.
    Lv, Qiu-yi
    Hou, Yao-yang
    Bao, Qi
    Lao, Li-xing
    Liu, Jian-ping
    Zhang, Ying
    Guyatt, Gordon H.
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2020, 20 (01)
  • [5] Effectiveness of physical exercise on the cardiovascular system in breast cancer patients: a systematic review and meta-analysis of randomized controlled trials
    Wang, Shurui
    Yang, Ting
    Qiang, Wanmin
    Shen, Aomei
    Zhao, Zihan
    Chen, Xing
    Xi, Chenxi
    Liu, Huan
    Guo, Fengli
    COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE, 2021, 44
  • [6] Tai Chi for Essential Hypertension: a Systematic Review of Randomized Controlled Trials
    Zhong, Dongling
    Li, Juan
    Yang, Han
    Li, Yuxi
    Huang, Yijie
    Xiao, Qiwei
    Liu, Tianyu
    Jin, Rongjiang
    CURRENT HYPERTENSION REPORTS, 2020, 22 (03)
  • [7] Reporting of analyses from randomized controlled trials with multiple arms: a systematic review
    Baron, Gabriel
    Perrodeau, Elodie
    Boutron, Isabelle
    Ravaud, Philippe
    BMC MEDICINE, 2013, 11
  • [8] Withdrawal reasons of randomized controlled trials on type 2 diabetes: a systematic review
    Mohseni, Shahrzad
    Tabatabaei-Malazy, Ozra
    Peimani, Maryam
    Ejtahed, Hanieh-Sadat
    Khodaeian, Mehrnoosh
    Nazeri, Elahe
    Nouhi, Zahra
    Khodamoradi, Kajal
    Aboeerad, Maryam
    Larijani, Bagher
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 29 (01) : 39 - 50
  • [9] Underrepresentation of women in randomized controlled trials: a systematic review and meta-analysis
    Daitch, Vered
    Turjeman, Adi
    Poran, Itamar
    Tau, Noam
    Ayalon-Dangur, Irit
    Nashashibi, Jeries
    Yahav, Dafna
    Paul, Mical
    Leibovici, Leonard
    TRIALS, 2022, 23 (01)
  • [10] Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials
    Shu, Xiangrong
    Chi, Liqun
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 1633 - 1641